Just caught Illumina's Q4 earnings and honestly it's a mixed bag. They crushed estimates on both EPS and revenue - adjusted EPS came in at $1.35, up 42% year-over-year, and revenues hit $1.16B. Should've been a green day, right? But the stock dips 10% after the announcement. Turns out everyone's worried about gross margin compression - it dropped 45 basis points due to rising costs. The company's guiding for 4-6% growth next year which seems solid on paper. I get that margin pressure is a concern, but the operational execution looks pretty clean - R&D spending down 6.6%, SG&A expenses down 11%. They also acquired SomaLogic and launched their new Billion Cell Atlas product. The fundamentals seem okay to me, but clearly the market's focused on that margin squeeze. Might be worth watching how they manage costs going forward.